pbs_code
stringlengths 5
6
| drug
stringclasses 15
values | brand
stringclasses 29
values | formulation
stringclasses 35
values | indication
stringclasses 7
values | treatment_phase
stringclasses 53
values | streamlined_code
stringclasses 33
values | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | schedule_code
int64 4.03k
4.03k
| schedule_year
int64 2.02k
2.02k
| schedule_month
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
9077R | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5284D | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5284D | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5284D | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5284D | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5284D | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5284D | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5284D | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5284D | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5284D | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5284D | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5284D | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5284D | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5284D | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5284D | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5284D | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12321L | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Initial treatment - Initial 1 (New patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12321L | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Initial treatment - Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12321L | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12806B | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9089J | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9089J | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9089J | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9089J | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9089J | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9089J | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9089J | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9089J | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5282B | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11979L | upadacitinib | Rinvoq | Tablet 15 mg | rheumatoid arthritis | First Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11979L | upadacitinib | Rinvoq | Tablet 15 mg | rheumatoid arthritis | First Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9090K | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9090K | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9090K | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9090K | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12810F | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
12810F | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
12568L | guselkumab | Tremfya | Injection 100 mg in 1 mL single use pre-filled pen | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12568L | guselkumab | Tremfya | Injection 100 mg in 1 mL single use pre-filled pen | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12568L | guselkumab | Tremfya | Injection 100 mg in 1 mL single use pre-filled pen | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12568L | guselkumab | Tremfya | Injection 100 mg in 1 mL single use pre-filled pen | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12568L | guselkumab | Tremfya | Injection 100 mg in 1 mL single use pre-filled pen | psoriatic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12568L | guselkumab | Tremfya | Injection 100 mg in 1 mL single use pre-filled pen | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13706J | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | rheumatoid arthritis | Subsequent continuing treatment | 14604 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12761P | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12396K | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
12396K | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
12396K | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
12396K | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
12396K | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
12396K | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
12396K | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
12396K | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
12396K | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
12396K | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
12396K | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
12396K | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
9460X | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9460X | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9460X | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9460X | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
1482B | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
1482B | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |